{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fibrillines : Questions médicales les plus fréquentes",
"headline": "Fibrillines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fibrillines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-24",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fibrillines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de la matrice extracellulaire",
"url": "https://questionsmedicales.fr/mesh/D016326",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de la matrice extracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D016326",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Fibrilline-1",
"alternateName": "Fibrillin-1",
"url": "https://questionsmedicales.fr/mesh/D000071838",
"about": {
"@type": "MedicalCondition",
"name": "Fibrilline-1",
"code": {
"@type": "MedicalCode",
"code": "D000071838",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300.400.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Fibrilline-2",
"alternateName": "Fibrillin-2",
"url": "https://questionsmedicales.fr/mesh/D000071840",
"about": {
"@type": "MedicalCondition",
"name": "Fibrilline-2",
"code": {
"@type": "MedicalCode",
"code": "D000071840",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300.400.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Fibrillines",
"alternateName": "Fibrillins",
"code": {
"@type": "MedicalCode",
"code": "D000071837",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Dieter P Reinhardt",
"url": "https://questionsmedicales.fr/author/Dieter%20P%20Reinhardt",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada. dieter.reinhardt@mcgill.ca."
}
},
{
"@type": "Person",
"name": "Clair Baldock",
"url": "https://questionsmedicales.fr/author/Clair%20Baldock",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, The University of Manchester, Manchester, UK."
}
},
{
"@type": "Person",
"name": "Gerhard Sengle",
"url": "https://questionsmedicales.fr/author/Gerhard%20Sengle",
"affiliation": {
"@type": "Organization",
"name": "Center for Biochemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Cologne Center for Musculoskeletal Biomechanics (CCMB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany."
}
},
{
"@type": "Person",
"name": "Stuart A Cain",
"url": "https://questionsmedicales.fr/author/Stuart%20A%20Cain",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell-Matrix Biology and Regenerative Medicine, Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom."
}
},
{
"@type": "Person",
"name": "Muthu L Muthu",
"url": "https://questionsmedicales.fr/author/Muthu%20L%20Muthu",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine, Department of Anatomy and Cell Biology, McGill University, Montreal, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.",
"datePublished": "2023-01-02",
"url": "https://questionsmedicales.fr/article/36595589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOS-D-22-00458"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychomodulatory substances: New legislative framework for control of psychoactive substances in Czechia.",
"datePublished": "2024-10-09",
"url": "https://questionsmedicales.fr/article/39388916",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugpo.2024.104603"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37348270",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.drugalcdep.2023.110819"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35947832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOS-D-22-00433"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents.",
"datePublished": "2024-05-31",
"url": "https://questionsmedicales.fr/article/38818605",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/jme.2024.60"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Scléroprotéines",
"item": "https://questionsmedicales.fr/mesh/D012596"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de la matrice extracellulaire",
"item": "https://questionsmedicales.fr/mesh/D016326"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fibrillines",
"item": "https://questionsmedicales.fr/mesh/D000071837"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fibrillines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fibrillines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fibrillines",
"description": "Comment diagnostiquer une déficience en fibrilline ?\nQuels examens sont utilisés pour évaluer les fibrillines ?\nLes tests génétiques sont-ils fiables pour les fibrillines ?\nQuels symptômes indiquent un problème de fibrilline ?\nPeut-on détecter des anomalies fibrillaires par imagerie ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fibrillines",
"description": "Quels sont les symptômes d'une maladie liée aux fibrillines ?\nLes douleurs articulaires sont-elles liées aux fibrillines ?\nY a-t-il des signes cutanés associés aux fibrillines ?\nLes problèmes oculaires sont-ils fréquents avec les fibrillines ?\nComment les anomalies cardiovasculaires se manifestent-elles ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fibrillines",
"description": "Peut-on prévenir les maladies liées aux fibrillines ?\nY a-t-il des conseils de mode de vie pour les patients fibrillaires ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nComment le suivi médical aide-t-il les patients ?\nLes activités physiques sont-elles sûres pour les patients ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fibrillines",
"description": "Quels traitements existent pour les troubles des fibrillines ?\nLa chirurgie est-elle nécessaire pour les problèmes de fibrillines ?\nDes médicaments peuvent-ils aider les patients fibrillaires ?\nY a-t-il des thérapies spécifiques pour les fibrillines ?\nComment gérer les douleurs liées aux fibrillines ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fibrillines",
"description": "Quelles sont les complications possibles des troubles fibrillaires ?\nLes complications cardiovasculaires sont-elles fréquentes ?\nComment prévenir les complications liées aux fibrillines ?\nLes douleurs chroniques sont-elles une complication courante ?\nLes problèmes respiratoires peuvent-ils être liés aux fibrillines ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fibrillines",
"description": "Quels sont les facteurs de risque pour les troubles des fibrillines ?\nLes antécédents familiaux augmentent-ils le risque ?\nLes mutations génétiques sont-elles un facteur de risque ?\nLes conditions médicales préexistantes influencent-elles le risque ?\nL'âge est-il un facteur de risque pour les troubles fibrillaires ?",
"url": "https://questionsmedicales.fr/mesh/D000071837?mesh_terms=Controlled+Substances&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en fibrilline ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests génétiques et des examens cliniques."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les fibrillines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie, l'IRM et les tests sanguins peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils fiables pour les fibrillines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques sont très fiables pour identifier les mutations des fibrillines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de fibrilline ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs articulaires et des anomalies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies fibrillaires par imagerie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'imagerie peut révéler des anomalies dans les tissus conjonctifs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une maladie liée aux fibrillines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, des problèmes cardiaques et des anomalies oculaires."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires sont-elles liées aux fibrillines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires peuvent être un signe de dysfonctionnement des fibrillines."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés aux fibrillines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cutanés comme des vergetures peuvent être observés en cas de déficience en fibrilline."
}
},
{
"@type": "Question",
"name": "Les problèmes oculaires sont-ils fréquents avec les fibrillines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes comme le décollement de la rétine peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les anomalies cardiovasculaires se manifestent-elles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent se manifester par des dilatations aortiques ou des ruptures vasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux fibrillines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter les problèmes tôt."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils de mode de vie pour les patients fibrillaires ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il les patients ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le suivi médical permet de surveiller l'évolution de la maladie et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres pour les patients ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des activités physiques modérées sont généralement sûres, mais doivent être adaptées à chaque patient."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles des fibrillines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la surveillance, la chirurgie et des médicaments pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle nécessaire pour les problèmes de fibrillines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être nécessaire pour corriger des anomalies cardiovasculaires graves."
}
},
{
"@type": "Question",
"name": "Des médicaments peuvent-ils aider les patients fibrillaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent aider à gérer les symptômes et à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies spécifiques pour les fibrillines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de thérapie spécifique, mais des soins symptomatiques sont offerts."
}
},
{
"@type": "Question",
"name": "Comment gérer les douleurs liées aux fibrillines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion de la douleur peut inclure des analgésiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des troubles fibrillaires ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des ruptures vasculaires, des problèmes cardiaques et des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications cardiovasculaires sont courantes et peuvent être graves."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux fibrillines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et un traitement approprié peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les douleurs chroniques sont-elles une complication courante ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir et nécessitent une gestion adéquate."
}
},
{
"@type": "Question",
"name": "Les problèmes respiratoires peuvent-ils être liés aux fibrillines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des problèmes respiratoires peuvent survenir en raison de complications pulmonaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des fibrillines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des conditions médicales."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de troubles fibrillaires augmente le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations génétiques sont directement liées aux troubles des fibrillines."
}
},
{
"@type": "Question",
"name": "Les conditions médicales préexistantes influencent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme le syndrome de Marfan augmentent le risque de complications."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles fibrillaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge peut influencer la gravité des symptômes, mais n'est pas un facteur de risque direct."
}
}
]
}
]
}
The purpose of this study is to identify the risk factors for prolonged opioid use after surgery in geriatric hip fracture patients and the effects of prolonged use on mortality and readmission rates....
An institutional registry was queried for all patients older than 65 years who underwent surgical treatment of a hip fracture between January 2016 and June 2017. Using the Controlled Substance Utiliza...
Of 500 patients who underwent hip-fracture surgery during the study period, a total of 322 had complete Controlled Substance Utilization Review and Evaluation System data. 36.0% (116) were OE, and 64....
Opioid use in geriatric hip fracture patients is high both preoperatively and postoperatively. Opioid exposed patients and patients on antidepressants are more likely to continue opioids at 6 months. ...
Level III....
This article challenges drug prohibition advocated by UN conventions as the prevailing regulatory model for psychoactive substances, highlighting its ineffectiveness, harmfulness and outdated nature. ...
Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team ...
To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription....
We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in ...
Of n=40 pharmacies, one or more of the requested controlled substances could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfe...
The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in t...
The United States opioid epidemic is a well-documented crisis stemming from increased prescriptions of narcotics. Online prescription drug monitoring programs (PDMPs) are a potential resource to mitig...
Patients who underwent a single-level lumbar fusion between August 27, 2017, and August 31, 2020, were identified and placed categorically into one of two cohorts: an "early adoption" cohort, Septembe...
No significant difference was observed in preoperative opioid prescriptions between the early and late adoption cohorts. The late adoption group independently predicted decreased postoperative opioid ...
PDMP implementation was associated with decreased postoperative opioid prescription patterns but not preoperative opioid prescribing behaviors....
4....
U.S. law imposes strict recording and reporting requirements on all entities that manufacture and distribute controlled substances. As a result, the prescription opioid crisis has unfolded in a data-s...
There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investig...
Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribe...
Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/o...
Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While ...
Tools that are directly integrated with the electronic health record (EHR) workflow can reduce the hassle cost of certain guideline-concordant practices, such as querying a prescription drug monitorin...
To investigate the effect of integrating access to a PDMP within the EHR on the frequency of program queries by primary care clinicians....
The PRINCE (Prescribing Interventions for Chronic Pain Using the Electronic Health Record) randomized trial used a factorial cluster design at the clinic level in 43 primary care clinics in Minnesota....
Single sign-on access to the Minnesota PDMP was integrated into the EHR, allowing clinicians to query a patient's controlled substance prescription and dispensing history as recorded in the Minnesota ...
Monthly PDMP query counts for primary care clinicians, overall and by modality (EHR-based, web-based, via a clinical delegate), adjusted for clinician characteristics, including type (physician, nurse...
Of the 43 participating clinics with 309 clinicians, 21 clinics with 161 clinicians (102 [63.4%] women; 114 [70.8%] physicians; tenure, 10.6 [4.4] years) received the PDMP integration intervention. Ba...
This cluster randomized clinical trial found that integrating access to the PDMP in the EHR increased PDMP-querying rates, suggesting that direct access reduced hassle costs and can dramatically impro...
ClinicalTrials.gov Identifier: NCT04601506....
While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool ...
Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant...
There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific t...
Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities....
A new FHIR-based (fast healthcare interoperability resource), EHR-integrated (electronic health record) application was created that embeds directly into prescribers' workflows. The intervention autom...
911 Good Samaritan Laws (GSLs) confer limited legal immunity to bystanders in possession of controlled substances who report emergency overdoses. While these laws may decrease opioid overdose mortalit...
We identified all state GSLs and their legislative history, characterizing features into four categories using a novel framework: breadth of protected activities, burden placed on Good Samaritans, str...
GSLs vary substantially across states and time. Protections depend on the quantity of substances involved and may extend to the person experiencing the overdose or persons reporting their own overdose...
States offer Good Samaritans substantially different protections even when the statutes confer nominally comparable immunities. Accommodating this heterogeneity will enhance the validity of future stu...